Using Modern Imaging Technology

Learn More

With new, proprietary drug formulations

Learn More

To precisely treat late stage and metastatic cancer

Learn More

and to stimulate a natural, adaptive immune response.

Learn More

Intensity Therapeutics is creating a new, highly effective cancer treatment - in situ vaccination.

Learn More

Intensity Therapeutics is a Qualified Connecticut Business


Intensity Therapeutics' is a "Qualified Connecticut Business" (QCB) as approved by CT Innovations. The State of Connecticut launched a program in 2010 that allows Angels providing capital to QCBs to take a credit against Connecticut State income tax for certain investments made in qualifying businesses. Investments must be at least $25,000 to be considered under the Program and the income tax credit equals 25% of the cash investment up to a maximum credit of $250,000.

 

Intensity Therapeutics is a clinical development stage company that is conducting human clinical testing of its lead product INT230-6 in refractory solid tumor cancers. The Company is interested in collaborating with pharmaceutical, imaging or biotechnology companies.  

 

Please contact Lew Bender via email at lbender@intensitytherapeutics.com or call our office at (203) 682-2434.

Contact Us


Intensity Therapeutics, Inc.
8 Wright Street, Suite 107
Westport, CT 06880


Tel. (203) 682-2434
Fax (203) 664-1051


info@intensitytherapeutics.com

 

Click here for career inquiries

Who we are


Intensity Therapeutics is a clinical development stage company.  We are seeking partnerships/investors interested in advancing the company’s anti-cancer platform technology and lead product INT230-6.

 

Click here for inquiries

News

Case number 01930099